Plaque Psoriasis: Seven-Market Drug Forecast and Market Analysis - Update (2025)

Table of Contents

Table of Contents

1 Plaque Psoriasis: Executive Summary - Updated July 2025, Based on Events Up to July 25, 2025

• 1.1 Summary of changes
• 1.2 PsO market to experience conservative growth from 2020-30
• 1.3 New players to enter a saturated field
• 1.4 Opportunities remain for undertreated patient populations
• 1.5 Innovator small molecules dominate the late-stage pipeline
• 1.6 What do physicians think?

2 Introduction

• 2.1 Catalyst
• 2.2 Related reports
• 2.3 Upcoming reports

3 Disease Overview

• 3.1 Etiology and pathophysiology
  • 3.1.1 Etiology
  • 3.1.2 Pathophysiology

4 Epidemiology

• 4.1 Disease background
• 4.2 Risk factors and comorbidities
• 4.3 Global and historical trends
• 4.4 Forecast methodology
  • 4.4.1 Sources
  • 4.4.2 Forecast assumptions and methods.
• 4.5 Epidemiological forecast for PsO (2020-30)
  • 4.5.1 Lifetime diagnosed prevalent cases of PsO
  • 4.5.2 Age-specific lifetime diagnosed prevalent cases of PsO
  • 4.5.3 Sex-specific lifetime diagnosed prevalent cases of PsO
  • 4.5.4 Lifetime diagnosed prevalent cases of PsO by severity in the adult population
  • 4.5.5 Lifetime diagnosed prevalent cases of PsO with PsA in the adult population
• 4.6 Discussion
  • 4.6.1 Epidemiological forecast insight
  • 4.6.2 COVID-19 impact
  • 4.6.3 Limitations of analysis
  • 4.6.4 Strengths of analysis

5 Disease Management

• 5.1 Diagnosis
• 5.2 Treatment

6 Competitive Assessment

• 6.1 Overview
  • 6.1.1 TNF inhibitors
  • 6.1.2 IL-17 inhibitors
  • 6.1.3 IL-12/23 inhibitors and IL-23 inhibitors
  • 6.1.4 PDE4 inhibitors
  • 6.1.5 Kinase inhibitors
  • 6.1.6 Other disease modifying therapies
• 6.2 Biosimilars

7 Unmet Needs and Opportunity Assessment

• 7.1 Overview
• 7.2 Cost-effective therapies
• 7.3 Efficacious therapies for treatment refractory patients
• 7.4 Lack of innovative topical therapies
• 7.5 Treatment options for mild PsO patients

8 R&D Strategies

• 8.1 Development shifts away from injectable biologics
• 8.2 New players enter the late-stage pipeline
• 8.3 Clinical trials design
  • 8.3.1 Robust clinical endpoints
  • 8.3.2 Long-term patient follow-up
  • 8.3.3 Active comparator trials

9 Pipeline Assessment - Updated July 2025, Based on Events Up to July 25, 2025

• 9.1 Overview
• 9.2 Promising drugs in clinical development
  • 9.2.1 Sonelokimab
  • 9.2.2 Icotrokinra
  • 9.2.3 TAK-279
  • 9.2.4 Orismilast
  • 9.2.5 Piclidenoson
• 9.3 Other drugs of note
  • 9.3.1 Balinatunfib (SAR441566)
  • 9.3.2 DC-806
  • 9.3.3 Mirikizumab
  • 9.3.4 Brepocitinib tosylate

10 Pipeline Valuation Analysis - Updated July 2025, Based on Events Up to July 25, 2025

• 10.1 Overview
• 10.2 Competitive assessment
  • 10.2.1 Biologic medications
  • 10.2.2 Small molecule therapeutics

11 Current and Future Players - Updated July 2025, Based on Events Up to July 25, 2025

• 11.1 Overview
• 11.2 Deal-making trends

12 Market Outlook - Updated July 2025, Based on Events Up to July 25, 2025

• 12.1 Global markets
  • 12.1.1 Forecast
  • 12.1.2 Drivers and barriers - global issues
• 12.2 US
  • 12.2.1 Forecast
  • 12.2.2 Key events
  • 12.2.3 Drivers and barriers
• 12.3 5EU
  • 12.3.1 Forecast
  • 12.3.2 Key events
  • 12.3.3 Drivers and barriers
• 12.4 Japan
  • 12.4.1 Forecast
  • 12.4.2 Key events
  • 12.4.3 Drivers and barriers

13 Appendix

• 13.1 Abbreviations
• 13.2 Methodology
  • 13.2.1 Forecasting methodology
• 13.3 Primary research - KOLs and payors interviewed for this report
  • 13.3.1 KOLs
  • 13.3.2 Payers
• 13.4 Bibliography
• 13.5 Primary research - prescriber survey
• 13.6 About the authors
  • 13.6.1 Analyst
  • 13.6.2 Managing Analyst
  • 13.6.3 Epidemiologist
  • 13.6.4 Reviewers
  • 13.6.5 Vice President of Disease Intelligence and Epidemiology
  • 13.6.6 Global Head and EVP of Healthcare Operations and Strategy
• About GlobalData
• Contact Us

List of Table

List of Tables

• Table 1: Plaque psoriasis: key metrics in the 7MM
• Table 2: Summary of changes to PsO: Seven-Market Drug Forecast and Analysis Report
• Table 3: Risk factors and comorbidities for PsO
• Table 4: Classification of PsO by BSA
• Table 5: Treatment guidelines for plaque psoriasis
• Table 6: Top completed deals in PsO market by value, 2018-23
• Table 7: PsO market - global drivers and barriers, 2020-30
• Table 8: Key events impacting sales for PsO in the US, 2020-30
• Table 9: PsO market - drivers and barriers in the US, 2020-30
• Table 10: Key events impacting sales for PsO in the 5EU, 2020-30
• Table 11: PsO market - drivers and barriers in the 5EU, 2020-30
• Table 12: Key events impacting sales for PsO in Japan, 2020-30
• Table 13: PsO market - drivers and barriers in Japan, 2020-30
• Table 14: High-prescribing physicians (non-KOLs) surveyed, by country

List of Figure

List of Figures

• Figure 1: Global sales forecast by country for PsO in 2020 and 2030
• Figure 2: Analysis of the company portfolio gap in PsO during the forecast period
• Figure 3: Competitive assessment of the pipeline/recently approved biologic drugs benchmarked against the SOC, Humira
• Figure 4: Competitive assessment of the pipeline small molecule drugs benchmarked against the SOC, Otezla
• Figure 5: Biologic and small molecule targets in the treatment of PsO
• Figure 6: 7MM, lifetime diagnosed prevalence of pediatric PsO (%), boys and girls, ages <=17 years, 2020
• Figure 7: 7MM, lifetime diagnosed prevalence of adult PsO (%), men and women, ages >=18 years, 2020
• Figure 8: Sources used for lifetime diagnosed prevalent cases of pediatric PsO
• Figure 9: Sources used and not used for lifetime diagnosed prevalent cases of PsO in adults
• Figure 10: Sources used for lifetime diagnosed prevalent cases of PsO by severity among adults
• Figure 11: Sources used for lifetime diagnosed prevalent cases of PsO with PsA among adults
• Figure 12: 7MM, lifetime diagnosed prevalent cases of PsO, men and women, all ages, 2020 (N)
• Figure 13: Age-specific lifetime diagnosed prevalent cases of PsO, 7MM, men and women, 2020 (N)
• Figure 14: 7MM, sex-specific lifetime diagnosed prevalent cases of PsO, all ages, 2020 (N)
• Figure 15: 7MM, lifetime diagnosed prevalent cases of PsO by severity, men and women, >=18 years, 2020
• Figure 16: 7MM, lifetime diagnosed prevalent cases of PsO with psoriatic arthritis, men and women, >=18 years, 2020 (N)
• Figure 17: Overall treatment algorithm for PsO as approved by the EMA
• Figure 18: Unmet needs and opportunities in PsO
• Figure 19: Overview of the development pipeline in PsO
• Figure 20: Key late-stage trials for the promising pipeline agents that GlobalData expects to be licensed for PsO in the 7MM during the forecast period
• Figure 21: Competitive assessment of the pipeline/recently approved biologic drugs benchmarked against the SOC, Humira
• Figure 22: Competitive assessment of the pipeline small molecules drugs benchmarked against the SOC, Otezla
• Figure 23: Analysis of the company portfolio gap in PsO during the forecast period
• Figure 24: Global (7MM) sales forecast by country for PsO in 2020 and 2030
• Figure 25: Sales forecast by class for PsO in the US in 2020 and 2030
• Figure 26: Sales forecast by class for PsO in the 5EU in 2020 and 2030
• Figure 27: Sales forecast by class for PsO in Japan in 2020 and 2030